IHAM
CYTK icon

Integral Health Asset Management’s Cytokinetics CYTK Stock Holding History

Integral Health Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,000
Closed -$8.35M – 86
2023
Q4 		$8.35M Buy
+100,000
New +$3.62M 1.14% 39

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Integral Health Asset Management's CYTK Position: Q2 2026 in Review

Integral Health Asset Management held its Cytokinetics (CYTK) position steady in Q2 2026 at 1,600,000 shares worth $136M. The position accounts for 5.38% of the portfolio, ranked #3.

Integral Health Asset Management first reported a position in CYTK in Q1 2020 and has held it in 26 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Integral Health Asset Management held 1,600,000 shares of Cytokinetics worth $136M as of Q2 2026.
  • Integral Health Asset Management left its Cytokinetics share count unchanged in Q2 2026.
  • Cytokinetics made up 5.38% of Integral Health Asset Management's portfolio in Q2 2026, its #3 holding.
  • Integral Health Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 26 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Integral Health Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.